It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite the salient benefits of the intravenous tissue plasminogen activator (tPA), symptomatic intracerebral hemorrhage (sICH) remains a frequent complication and constitutes a major concern when treating acute ischemic stroke (AIS). This study explored the use of artificial neural network (ANN)-based models to predict sICH and 3-month mortality for patients with AIS receiving tPA. We developed ANN models based on evaluation of the predictive value of pre-treatment parameters associated with sICH and mortality in a cohort of 331 patients between 2009 and 2018. The ANN models were generated using eight clinical inputs and two outputs. The generalizability of the model was validated using fivefold cross-validation. The performance of each model was assessed according to the accuracy, precision, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). After adequate training, the ANN predictive model AUC for sICH was 0.941, with accuracy, sensitivity, and specificity of 91.0%, 85.7%, and 92.5%, respectively. The predictive model AUC for 3-month mortality was 0.976, with accuracy, sensitivity, and specificity of 95.2%, 94.4%, and 95.5%, respectively. The generated ANN-based models exhibited high predictive performance and reliability for predicting sICH and 3-month mortality after thrombolysis; thus, its clinical application to assist decision-making when administering tPA is envisaged.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Taipei Medical University - Shuang Ho Hospital, Department of Neurology, New Taipei, Taiwan (GRID:grid.412955.e) (ISNI:0000 0004 0419 7197); Taipei Medical University, Department of Neurology, School of Medicine, College of Medicine, Taipei, Taiwan (GRID:grid.412896.0) (ISNI:0000 0000 9337 0481); Taipei Medical University, Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei City 110, Taiwan (GRID:grid.412896.0) (ISNI:0000 0000 9337 0481)
2 Taipei Medical University - Shuang Ho Hospital, Department of Neurology, New Taipei, Taiwan (GRID:grid.412955.e) (ISNI:0000 0004 0419 7197); Taipei Medical University, Department of Neurology, School of Medicine, College of Medicine, Taipei, Taiwan (GRID:grid.412896.0) (ISNI:0000 0000 9337 0481)
3 Taipei Medical University - Shuang Ho Hospital, Department of Hematology and Oncology, Cancer Center, New Taipei, Taiwan (GRID:grid.412955.e) (ISNI:0000 0004 0419 7197); Taipei Medical University - Shuang Ho Hospital, Department of Medical Research and Education, New Taipei, Taiwan (GRID:grid.412955.e) (ISNI:0000 0004 0419 7197)
4 Taipei Medical University Hospital, Clinical Big Data Research Center, Taipei, Taiwan (GRID:grid.412897.1) (ISNI:0000 0004 0639 0994); Taipei Medical University, Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei City 110, Taiwan (GRID:grid.412896.0) (ISNI:0000 0000 9337 0481)